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13.05.002Abstract Cardiovascular disease (CVD) is a leading cause of morbidity and mortality. The risk
factors for CVD include environmental and genetic components. Human mutations in genes
involved in most aspects of cardiovascular function have been identiﬁed, many of which are
involved in transcriptional regulation. The Mediator complex serves as a pivotal transcriptional reg-
ulator that functions to integrate diverse cellular signals by multiple mechanisms including recruit-
ing RNA polymerase II, chromatin modifying proteins and non-coding RNAs to promoters in a
context dependent manner. This review discusses components of the Mediator complex and the
contribution of the Mediator complex to normal and pathological cardiac development and func-
tion. Enhanced understanding of the role of this core transcriptional regulatory complex in the
heart will help us gain further insights into CVD.Introduction
Cardiovascular disease (CVD) is attributed as the cause of
death for approximately 17 million people worldwide in 2008
[1]. Estimates predict that by 2030, over 23 million people will
die due to complications involving CVD [1,2]. The risk factors
for CVD include genetic abnormalities, metabolic-related dis-
eases and lifestyle choices [3]. Many of the risk factors including
physical inactivity, poor diet, obesity and diabetes result in dra-
matic changes in systemic metabolism [4]. The combinations ofrueter CE).
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ing Institute of Genomics, Chinese ACVD and type 2 diabetes risk factors are components of the
metabolic syndrome [5]. As the 10 year risk factor for develop-
ing CVD doubles in patients with metabolic syndrome, a logi-
cal clinical goal is to reduce these risk factors [6].
The intricate patterns of gene expression during normal and
disease states are governed by elaborate signaling pathways
that converge on the transcriptional machinery. Eukaryotic
cells have adapted the transcriptional machinery in order to
integrate a plethora of environmental signals, a mechanism vi-
tal to maintain homeostasis. The general transcriptional
machinery can be recruited to promoters by the Mediator com-
plex [7–9]. The Mediator complex functions as part of the pre-
initiation complex that directly binds to and transduces signals
from transcription factors [10]. Adaptation to changes in the
physiological state of a cell occurs through multiple processes.
These include chromatin modiﬁcation, long non-coding RNAs
(ncRNAs), microRNAs (miRNAs) and transcription elonga-
tion factors that signal to the transcriptional machinery in partcademy of Sciences and Genetics Society of China. Production and hosting
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Figure 1 Model representing regulation of Mediator-dependent transcription
The Mediator complex coordinates the input from signal-dependent transcription factors (TFs) to recruit RNA polymerase II (RNAPII)
and regulate the expression of RNAPII-dependent genes. Chromatin modiﬁers (GCN5L and CBP/p300), non-coding RNAs including
long non-coding RNAs (ncRNA-a) and microRNAs (miR-208a, miR-378 and 378*), and elongation factors including P-TEFb converge
at the Mediator complex to integrate cellular signals resulting in the activation or repression of transcription.
152 Genomics Proteomics Bioinformatics 11 (2013) 151–157through interaction with the Mediator complex to regulate
gene expression (Figure 1) [11,12]. This review focuses on our
current understanding of the Mediator complex in cardiovas-
cular development and disease.
The function of the Mediator complex
The Mediator complex is conserved in eukaryotes and func-
tions to integrate signal-speciﬁc events and direct transcription
at multiple levels [13,14]. Mediator is a large, multi-subunit
complex consisting of more than 26 proteins that forms the
pre-initiation complex, recruiting RNA polymerase II (RNA-
PII) to ensure proper regulation of gene expression [10]. Multi-
ple components of the Mediator complex bind to signal-
dependent transcription factors including nuclear hormone
receptors, regulating the transcription of target genes [15–17].
This molecular bridge between DNA-bound transcription fac-
tors and the general transcription machinery provides an intri-
cate platform for transcriptional control [13,14]. Among the
many known functions of the Mediator complex is the recruit-
ment of other transcriptional regulatory complexes including
chromatin modifying enzymes such as GCN5L and CBP/
p300 [18–21]. Recently, Mediator has been shown to function
in conjunction with non-coding RNAs to regulate transcrip-
tion [22,23]. Thus, Mediator functions to regulate transcription
at multiple points in the process of gene expression.
The Mediator complex can be divided into four structural
modules. The head, middle and tail modules make up the core
Mediator complex [24–28]. The interaction between the core
complex and transcription factors such as the thyroid hormone
receptor, vitamin D receptor, sterol-response-element-binding
protein (SREBP) and nuclear factor-kB (NF-kB) was essential
in the early identiﬁcation of the mammalian Mediator complex
[29–32]. The fourth module of the Mediator complex is the ki-
nase submodule which consists of MED13, MED12, cyclin C
and cyclin-dependent kinase 8 (CDK8) [33–35]. In mammals,
there are homologs of MED13, MED12 and CDK8, which
are MED13-like (MED13L), MED12-like (MED12L) and
CDK19, respectively [36]. Biochemical analysis of the compo-
sition of the Mediator complex demonstrates two majorsubclasses, the large complex containing all four modules
and the smaller complex which lacks the kinase submodule
[37]. The reversible interaction and structural studies of the ki-
nase submodule with the core Mediator complex suggest that
the interactions between the kinase submodule and RNAPII
to the Mediator complex are mutually exclusive [34]. The di-
verse and still incompletely understood functions of the kinase
submodule also include direct interactions with chromatin
modifying complexes that further function to repress gene
transcription [38–40]. While the majority of studies demon-
strate the repressive function of the kinase submodule, recent
studies have found that the kinase submodule can also func-
tion in some contexts to enhance transcription [41,42].
Mediator in human disease
The number of Mediator complex genetic mutations that are
associated with speciﬁc human disease is increasing. The list
of phenotypes directly associated with the Mediator complex
malfunction includes multiple forms of cancer, neurodevelop-
ment and behavioral disorders as well as cardiovascular dis-
eases. A number of excellent reviews describe in detail the
conservation, function and mutations associated with the
Mediator complex [12,43–48]. Brieﬂy, misregulation of
MED1 [49,50], MED12 [51], MED19 [52], MED23 [53],
MED28 [54], MED29 [55], CDK8 and CycC [56,57] have all
been implicated in various forms of cancer. Multiple human
neurodevelopmental diseases are associated with mutations
in or altered functions of MED12 [58], MED17 [59], MED23
[60], MED25 [61], CDK19 [62] and CycC [63], while mutations
in MED13 [64,65] and MED13L [66,67] have been linked to
CVD.
Defects in cardiac development represent approximately
1% of severe birth defects [68,69]. The high prevalence of con-
genital heart disease raises the question of the underlying cause
of the defect. In 2003, mutations in human MED13L, also
known as Prosit240 or TRAP240-like, were identiﬁed to be
correlated with transversion of the great arteries [67]. Recently,
two groups have independently reported changes in MED13L
expression levels: haplosufﬁciency or duplication supports the
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heart defects [66,70]. Consistent with these ﬁndings, expression
studies showed that MED13L is enriched in the heart and fur-
ther examination revealed relatively high expression of
MED13L in the aorta [67]. Together, these studies demon-
strate the signiﬁcant role of MED13L in cardiovascular devel-
opment. The mechanism for regulation of MED13L
expression and function remains unclear and warrants future
studies.
Identiﬁcation of human mutations in the MED13 gene re-
veals a broader phenotype affecting multiple organs. The clin-
ical report of an 800-kb region of chromosome 17 containing
multiple genes including MED13 suggests haplosufﬁciency in
human MED13 may result in developmental abnormalities
including small stature, cognitive defects and hearing loss
[65]. Further evaluation of MED13 mutations revealed other
patients with similar phenotypes [65]. Studies focusing on
RNA editing have identiﬁed MED13 as an important target
for A to I editing in both brain tumor and cyanotic congenital
heart disease [65,71]. This information may provide insight
into the mechanism for the Mediator complex-dependent reg-
ulation of gene expression in normal and diseased states.
Mediator in cardiac disease models
The core Mediator complex is a vital component of eukaryotic
transcription [72], potentially explaining why relatively few hu-
man mutations have been identiﬁed. However, genetic studies
of the Mediator complex demonstrate that select components
of Mediator are critical for the survival of the multicellular
organism but are not necessary for individual cell survival
[72–75]. Mutation of peripheral components of the Mediator
complex such as MED1 [76,77], MED12 [75], MED13 [78],
MED30 [79] and CDK8 [80] in vivo provide tools to study
the intricate processes of Mediator-dependent transcriptional
regulation.
Despite the link between Mediator and disease described
above, few studies have addressed the role of Mediator in
CVD. What has been addressed utilizing powerful genetic
tools, RNA proﬁling and metabolic phenotyping has garnered
a better understanding of the Mediator complex and its role in
CVD.
Mutation of MED30 in the mouse heart results in lethal
cardiomyopathy due to altered mitochondria [79]. Homozy-
gous missense mutations in MED30, an isoleucine to phenylal-
anine substitution at amino acid 44 (I44F) resulting in a
hypomorphic allele allowing postnatal survival, leads to car-
diomyopathy that can be partially rescued by a ketogenic diet
[79]. However, the mutation results in a progressive dilated
cardiomyopathy in young adult mice. The cardiomyopathy is
manifested by a dramatic decline in mitochondrial oxidative
phosphorylation capacity measured by a decrease in respira-
tory chain function and a decrease in mRNA levels of oxida-
tive phosphorylation genes potentially due to inefﬁcient
activation of the transcriptional cofactor PPARGC1A (PGC-
1a), a key transcriptional regulator of oxidative phosphoryla-
tion gene expression that directly interacts with MED1 [20,81].
Interestingly, a component of the core Mediator complex,
MED1, was previously identiﬁed in biochemical analysis as a
peroxisome proliferator-activated receptor-interacting protein
(PRIP) [82,83]. MED1 mutant mice are embryonically lethalat around E11.5 as reported by the Reddy and Roeder groups
independently [77,84,85]. Both groups report multiple histo-
logical defects in MED1 null mice including thinning of the
myocardial compaction layer [50,77]. Further independent
studies using a homozygous MED1 hypomorphic allele dem-
onstrate blunted cardiac development in embryos that survive
to E13.5 [86]. While these studies clearly demonstrate the
requirement for MED1 in development, studies demonstrating
the role of MED1 in cardiac speciﬁc development and function
have not been reported. However, conditional deletion of
MED1 in the skeletal muscle and the liver demonstrates a role
for MED1 in regulating metabolic homeostasis in obesity
studies [87,74].
Mediator regulation of metabolism inﬂuences CVD
Recently, multiple organs not traditionally considered to be
regulators of metabolism have been implicated in the regula-
tion of whole-body energy expenditure including the heart
and the skeletal muscle [78,88,89]. The traditional function
of the heart is to supply the rest of the body with nutrients.
Maintenance of cardiac contractility requires a high capacity
for ATP generation. It is estimated that the heart stores en-
ough energy to sustain function for only a few beats [90]. Thus
myocardial metabolism must be highly regulated in response
to changes in physiological, pathological and developmental
conditions [90]. The heart consumes energy, mainly in the form
of fatty acid oxidation, at a high rate and can adapt to changes
in the supply of energy by ﬁne-tuning cardiac metabolism and
altering gene expression to maximize energy efﬁciency [90,91].
During cardiovascular diseased states, mitochondrial function
is diminished and the heart shifts from b-oxidation toward a
glycolytic metabolism [90,92]. Alterations in gene expression
occur through signal dependent transcription factors such as
SREBP and the cofactors associated with them. SREBP regu-
lates lipid signaling and is thus a key regulator of the enzymes
necessary for proper lipid utilization and homeostasis [93].
A recent study has demonstrated that CDK8 regulates
SREBP actions by directly phosphorylating the nuclear
mSREBP leading to degradation [94]. Further work implicat-
ing Mediator in metabolism includes studies in Caenorhabditis
elegans demonstrating that MED15 regulates fatty acid metab-
olism by mediating nuclear hormone receptor-dependent tran-
scription [95]. Additional studies demonstrate that MED23 is
involved in the regulation of insulin signaling and cell fate
determination in both adipogenesis and smooth muscle cell
differentiation [96,97]. MED1, a core protein of the Mediator
complex, binds directly to nuclear hormone receptors and is
necessary for maintaining energy homeostasis in skeletal mus-
cle [74,82,83]. Taken together, the role of Mediator in regulat-
ing metabolism is evident. Further studies are necessary to
determine its mechanism and function in cardiovascular
diseases.
The Mediator complex functions to regulate RNAPII-
dependent gene expression at multiple stages of transcription
including elongation by regulating super-elongation complexes
through MED23, MED26 and CDK8 [98,99]. Reduction of
CDK8 results in a decrease in the phosphorylation of RNAPII
C-terminal domain (CTD) and transcriptional elongation [41].
One of the functions of CDK8 is to recruit CDK9, the catalytic
subunit of the positive transcription elongation factor
154 Genomics Proteomics Bioinformatics 11 (2013) 151–157(P-TEFb), to the elongation machinery, suggesting a potential
role for CDK8 in the regulation of cardiac disease [41].
Interestingly, recent studies demonstrate a direct interaction
between MED23 and CDK9 to recruit P-TEFb to MED23-
dependent promoters [100]. P-TEFb can phosphorylate RNA-
PII CTD. Studies of P-TEFb in the heart demonstrate that
CDK9 is activated in cardiac hypertrophy [101] and the activa-
tion of CDK9 suppresses the expression of PGC1, resulting in
mitochondrial dysfunction and thus contributing to apoptotic
cardiomyopathy [102].
The function of the Mediator complex in transcriptional
regulation in vivo is exceedingly complex and incompletely
understood. However, the role of Mediator in the regulation
of metabolism is becoming increasingly evident
[74,76,78,103]. Our previous work on MED13 in the heart
demonstrates the heart’s ability to regulate systemic energy
homeostasis [78]. MED13 cardiac transgenic mice demonstrate
a resistance to diet-induced obesity due to enhanced energy
expenditure, while the cardiac deletion of MED13 results in
an enhanced susceptibility to diet-induced obesity. Speciﬁcally,
MED13 functions to regulate the transcription of a select sub-
set of genes, resulting in altered cardiac gene expression [78].
Although the previous studies of MED13 are of great interest,
further studies are needed to deﬁne the precise mechanism of
gene regulation by the Mediator kinase submodule.Modulation of the Mediator by ncRNAs
Mediator regulates RNAPII-dependent gene expression which
includes both protein-coding RNAs and ncRNAs. Of great
interest is a class of ncRNAs known as long ncRNAs (lncR-
NAs). The vast majority of lncRNAs have unknown functions
[104]. However, known functions of lncRNAs vary from mod-
ifying gene splicing, to imprinting as well as regulating post-
transcriptional events [104]. Recently, Lai et al. reported a
subclass of lncRNAs, ncRNA-a, which functions as a tran-
scriptional activator [22]. Interestingly, transcriptional activa-
tion by ncRNA-a requires the Mediator complex, speciﬁcally
MED12. Together, MED12 and ncRNA-a function to regu-
late chromatin looping. Mutations in MED12 identiﬁed in
the FG Syndrome reduce the interaction between MED12
and ncRNA-a, suggesting that ncRNA-a may play a signiﬁ-
cant role in human disease processes [22].
In addition to lncRNAs, a second class of ncRNAs, miR-
NAs have been shown to be key modiﬁers of human disease
and serve as biomarkers for disease states [3]. miRNAs are
small regulatory RNAs about 22 nucleotides in length that
function to repress the translation of mRNA, enhance mRNA
degradation or in some instances enhance the translation of
speciﬁc mRNA targets [105]. Multiple studies have shown
posttranscriptional modiﬁcation of Mediator protein expres-
sion by miRNAs [78,106–109]. A cardiac speciﬁc miRNA,
miR-208a regulates stress-dependent cardiomyocyte growth
and gene expression partially by the regulation of MED13
[108]. Therapeutic manipulation of miR-208a expression using
an antimiR protects against models of CVD and metabolic
syndrome [78,110]. Similarly, genetic deletion of miR-378
and 378* targets multiple mRNAs including MED13 to regu-
late systemic energy homeostasis [106]. Together, these studies
represent mechanisms to regulate the Mediator complex in
response to stress.Concluding remarks
Genetic evidence demonstrates the importance of the compo-
nents of the Mediator complex for normal development of
multi-tissue organisms. The Mediator complex has been shown
to play an important role in numerous aspects of development
and diseased states. The recent increase in human genetic dis-
orders revealed to be associated with mutations in various
components of the Mediator complex demonstrates the need
for the development of animal models to further our under-
standing of this evolutionarily conserved transcription regula-
tory complex. Despite the vast amount of studies done
deciphering the role of the Mediator complex, few studies have
demonstrated tissue speciﬁc functions for transcriptional regu-
lation in mammals. Further studies of the many components
of Mediator in a context speciﬁc manner are warranted. The
identiﬁcation and characterization of novel therapeutic targets
regulating components of the Mediator complex such as miR-
208a, miR-378 and 378*, compounds regulating CDK8 activ-
ity or chromatin modifying enzymes recruited by Mediator,
promise to offer insight into the intricate process of Media-
tor-dependent transcriptional regulation in normal cardiac
development and disease.
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